Highlights for April 2017

  1. Capital International buys 3% stake in India based Intas Pharmaceuticals for $107 million
  2. Serum Institute of India acquires Czech Republic's Nanotherapeutics
  3. Sayre Therapeutics enters into agreement with Spanish company GP Pharm
  4. CRISPR Therapeutics and Casebia Therapeutics Announce Exclusive Development and Option Agreement with StrideBio
  5. Microbiome biotech Finch Therapeutics signs pact with Takeda to jointly work on FIN-524
  6. J&J is paying up to $1.15 billion to enlist PeptiDream to aim its peptide discovery platform at multiple cardiovascular and metabolic targets
  7. Astellas to buy GPCR specialist Ogeda for €500M upfront
  8. Bristol-Myers sells anti-tau, DMD assets to Biogen, Roche for $470M upfront, $615M in milestones
  9. Novartis signs collaboration deal with tiny Parvus for diabetes nanomedicine
  10. Fledgling biotech Vtesse in $200M buyout from Sucampo
  11. Nimbus in full-on drug development partnership with Charles River

For more such news and updates, please join our Group "Global Life Science Business Partnering" on LinkedIn.

Updates at Aagami:

  • New Client Win for Aagami. UK based Client is has unique nanotechnology based delivery system that works with multiple forms such as topical, oral and injectable
  • Aagami client JRF Global completes an action packed result focused trip to California. Both CEOs and also JRF BD Head North America were present
  • Aagami registers for BIO International Convention June 19-22, 2017, in San Diego
  • Aagami CEO to visit Japan, Korea, India in August 2017